Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Dxlab Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. Prosecution is currently limited to 1 distinct examiner and 1 distinct art unit. SWITZER, JULIET CAROLINE is the busiest examiner, managing 1 pending office action.
This portfolio shows a narrow prosecution focus, with all active matters residing with 1 examiner. The presence of only 1 pending office action indicates a low volume of current activity at the patent office. For the practitioner, this means that the immediate success of the portfolio depends on the interaction with this 1 examiner. There are no other pending actions to provide a baseline for comparison within the company's current filings. Consequently, the strategy for Dxlab Inc. must be customized to the specific requirements of SWITZER, JULIET CAROLINE. The concentration in 1 distinct art unit further suggests that the company's current patenting efforts are focused on a specific niche within the broader biotechnology field, requiring specialized expertise during the response process. Each communication with the 1 examiner is critical for the development of the company's intellectual property assets.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SWITZER, JULIET CAROLINE | 1 | 42.8% | +53.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18260447 | METHODS FOR DETECTION OF NUCLEIC ACIDS | SWITZER, JULIET CAROLINE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18260447 | METHODS FOR DETECTION OF NUCLEIC ACIDS | SWITZER, JULIET CAROLINE | — |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18260447 | METHODS FOR DETECTION OF NUCLEIC ACIDS | SWITZER, JULIET CAROLINE | 1682 | §103§112Other | Non-Final OA | — | Pending | Jul 05, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDxlab Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Juliet Caroline Switzer has the most, with 1 of Dxlab Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.